Lornoxicam is a medication belonging to the class of nonsteroidal anti-inflammatory drugs (NSAIDs). It is mainly used for the relief of pain and inflammation.
Lornoxicam (Dosage)
Lornoxicam is an NSAID analgesic belonging to the oxicam class, used for mild to moderate acute and chronic pain and also acts as an anti-inflammatory and antipyretic. It is indicated for musculoskeletal pain, postoperative pain, inflammation in rheumatoid arthritis, osteoarthritis, acute lumbar-sciatic conditions, dysmenorrhea, and soft tissue inflammation.
MECHANISM OF ACTION
Lornoxicam is a potent inhibitor of cyclooxygenase enzymes (COX-1 and COX-2), which acts by reducing the synthesis of prostaglandins, substances that mediate pain, inflammation, and fever.
CONTRAINDICATIONS
Lornoxicam treatment is contraindicated in the following cases:
- Patients with hypersensitivity to NSAIDs, including acetylsalicylic acid.
- Acute heart failure.
- History of gastrointestinal perforation or bleeding related to the use of NSAIDs.
- Presence of active or previous gastrointestinal ulcers or bleeding.
- Cerebrovascular hemorrhages or other types of active bleeding.
- During the third trimester of pregnancy.
- Patients with acute renal or hepatic failure.
SIDE EFFECTS
The most frequent adverse reactions are mild headache, dizziness, nausea, abdominal pain, dyspepsia, diarrhea, vomiting.
INTERACTIONS
Lornoxicam can interact with multiple medications, so it is recommended to inform your doctor of all the medications you are taking. Lornoxicam interacts with NSAIDs (such as acetylsalicylic acid and ibuprofen) and anticoagulant agents (such as warfarin) and antiplatelet agents (e.g., clopidogrel) and may lead to an increased risk of bleeding. NSAIDs decrease the therapeutic effect of antihypertensive drugs and should be used with caution in patients with underlying hypertension. It also interacts with corticosteroids, cimetidine, immunosuppressants, lithium, selective serotonin reuptake inhibitors (SSRIs), sulfonylureas, and some antibiotics, among other medications.
BRAND NAMES
- Acabel®
- Bosporón®
- Lormex®
- Lornicam®
- Lornoxicam Rapid meiji®
- Taigalor®
- Xefo®
- Xefocam®
Genes analyzed
Bibliography
Choi CI, Kim MJ, Jang CG, et al. Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam. Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):476-80.
Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020 Aug;108(2):191-200.
